Menu
Washingtoner
  • Home
  • Business
  • Construction
  • Technology
  • Arts
  • Health
  • Property
  • Software
  • Marketing
Washingtoner

Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust
Washingtoner/10189896

Trending...
  • Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
  • Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
  • Blake Harris the Leading Authority in International Asset Protection Joins Tom Hegna on "Financial Freedom with Tom Hegna"
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Omeros has sold to DRI Healthcare Acquisitions LP ("DRI"), a wholly owned subsidiary of DRI Healthcare Trust, an interest in certain royalty payments based on net sales of OMIDRIA (the "Purchased Receivables"). The royalties payable to DRI comprise a portion of the royalties projected to be paid under the terms of the Asset Purchase Agreement (the "Asset Purchase Agreement"), among Omeros, Rayner Surgical Inc. ("Rayner Surgical") and Rayner Surgical Group Limited, pursuant to which Omeros sold OMIDRIA and related business assets to Rayner Surgical in December 2021.

Omeros received gross proceeds from DRI of $125 million upon closing of the sale of the Purchased Receivables, which was completed pursuant to a Royalty Purchase Agreement between Omeros and DRI, dated September 30, 2022 (the "Royalty Purchase Agreement").

Under the Royalty Purchase Agreement, DRI is entitled to royalties on net sales of OMIDRIA received between September 1, 2022 and December 31, 2030, subject to annual caps. Based on the payment schedule and associated caps, not until July 2028 will DRI have been paid an aggregate of $125 million, the amount that Omeros has received from DRI. Specifically, the caps are set at $1.67 million for the remainder of 2022, $13 million for calendar year 2023, $20 million for calendar year 2024, $25 million for calendar years 2025 through 2028, $26.25 million for calendar year 2029 and $27.50 million for calendar year 2030. The total payments to DRI throughout the term of the agreement are $188.4 million and represent no more than one-third of future royalty payments projected to be paid by Rayner to Omeros through 2030.

DRI is not entitled to carry-forward nor recoup any shortfall if the royalties paid by Rayner for an annual period are less than the cap amount applicable to such period. Omeros will retain all royalties received during a given annual period in excess of the respective cap. DRI has no recourse to Omeros' assets other than the Purchased Receivables and is entitled to payment for the Purchased Receivables only to the extent of royalty payments actually received, up to the previously described annual caps. Given that this is a partial sale of OMIDRIA royalties, there are no asset pledges or financial covenants.

More on Washingtoner
  • Spokane River Flows Meet Level 2 Drought Response
  • California Family Launches Billboard to Reach "Pardon Czar" Alice Marie Johnson
  • Rent Like A Champion Acquires CollegeWeekends
  • Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
  • Seligson Law Launches New Website to Support Cannabis Businesses in California and New York

Royalty payments, as received from Rayner, will be allocated between Omeros and DRI each month based on the amount to which DRI is entitled. Monthly caps are determined by dividing the annual cap amount by 12 or, in the case of the partial calendar year 2022, by four.

"We are pleased to have partnered with DRI to monetize a portion of our OMIDRIA royalty stream," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "The transaction provides Omeros with a substantial capital infusion that is repayable over the next eight and a half years solely from future OMIDRIA royalties, retains the majority of our expected OMIDRIA revenues, and does not dilute our stockholders."

The Purchased Receivables do not include, and DRI is not entitled to, any portion of the $200 million commercial milestone payment payable to Omeros under the Asset Purchase Agreement if, before January 1, 2025, separate payment for OMIDRIA under Medicare Part B is secured for a continuous period of at least four years.

OMIDRIA has been granted separate payment in ambulatory surgery centers by the Centers for Medicare and Medicaid Services (CMS) under CMS' non-opioid alternative pain management exclusion from packaged payment. The most recently reported quarterly net revenues for OMIDRIA were $34.5 million for the quarter ended June 30, 2022, on which Omeros earned a 50-percent royalty, or $17.2 million, from Rayner.

About Omeros Corporation

Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application (BLA) pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, COVID-19, and atypical hemolytic uremic syndrome. Omeros' long-acting MASP-2 inhibitor OMS1029 is currently in a Phase 1 clinical trial. OMS906, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria (PNH), complement 3 (C3) glomerulopathy and one or more related indications. For more information about Omeros and its programs, visit www.omeros.com.

More on Washingtoner
  • South Tacoma Groundwater Protection District Code Update Public Hearing on August 12
  • databahn Announces Subscription Access to Fortune 500 GenAI Deep Dive Sales Intelligence Reports
  • AI startup Congero offers instant websites with 24/7 updates - aiming to replace web agencies
  • WonderDays Launches the UK's First AI Experience Gift Finder – Gifting Just Got So Much Easier!
  • CelluHeal™ Launches Full Line of Advanced Wound Dressings for Online Purchase in the USA, Canada, and Beyond

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the "safe harbor" created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "likely," "look forward to," "may," "objective," "plan," "potential," "predict," "project," "should," "slate," "target," "will," "would" and similar expressions and variations thereof. Forward-looking statements, including projections of future royalties payable based on net sales of OMIDRIA, are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with product commercialization and commercial operations, regulatory processes and oversight, payment and reimbursement policies applicable to OMIDRIA and the risks, uncertainties and other factors described under the heading "Risk Factors" in the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 1, 2022. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Contacts

Jennifer Cook Williams
Cook Williams Communications, Inc.
Investor and Media Relations
IR@omeros.com
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • "The Pornified Generation": Dr. Chris Samuels Exposes the Toxic Alliance Between Bro Culture and Pornography That's Rewiring a Generation
  • Spokane: Suspect in custody after deliberately set fire causes damage to building housing the Downtown Police Precinct
  • Multi-Agency Response Controls Dual Fires in Spokane
  • MoVO Media Marketing Expands CRE Marketing Powerhouse with Addition of Fly Jamerson
  • The Modern Insurance Store Expands Medicare Help Services for Seniors in Cincinnati
  • Hire a Business Plan Writer: What to Expect and Why It's Worth It
  • Ironside HR Named Fastest-Growing Staffing Firm for Second Year
  • Inframark Continues to Build Its Community Management Capabilities and Multi-Disciplinary Presence in Arizona
  • ICAST 2025: The Crystal-Clear Revolution Begins at Booth #3233
  • Brindle Pet Supplies Now Carries Badlands Ranch Dog Food in Canada
  • $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
  • Sing For Your Supper: A Night of Musical Comedy and Drag for a Great Cause
  • Arcadis welcomes transportation leader Greg Spotts to advance mobility in Seattle and California
  • Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
  • $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
  • New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
  • SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
  • TikTok Star ArcadeFriends Attempts 24-Hour Claw Machine Marathon at Lucky Puppy Arcade in Las Vegas
  • Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
  • Annual Snapshot Estimate of Spokane County's Homeless Population Shows Overall Decrease for Second Year in a Row
_catLbl0 _catLbl1

Popular on Washingtoner

  • purelyIV Blog Named One of the Top 45 IV Therapy Blogs by Feedspot - 136
  • GMO Miner: Creating a simple, efficient and reliable new cloud mining experience - 133
  • Exciting News: Pivotal Health Solutions Acquires Revolutionary Portable Parallel Bars - 129
  • Agreement to Supply US-Based Defense Provider with Thin-Film Solar Tech for Orbital Application; Ascent Solar Technologies, Inc. (N A S D A Q: ASTI) - 109
  • West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care - 103
  • New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient - 101
  • New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives - 101
  • Eolian Signs New Information Exchange Agreement with the U.S. Department of Defense for Technology Innovation
  • DCAS College opens new Representative Office in Malaysian Capital Kuala Lumpur
  • Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI

Similar on Washingtoner

  • Pixel Studio Productions Launches Same-Day Headshots in Houston
  • SeedList Launching Institutional Crypto Crowdfunding Project to Empower Retail Investors and Disrupt the VC-Dominated Crypto Fundraising Landscape
  • Seligson Law Launches New Website to Support Cannabis Businesses in California and New York
  • databahn Announces Subscription Access to Fortune 500 GenAI Deep Dive Sales Intelligence Reports
  • AI startup Congero offers instant websites with 24/7 updates - aiming to replace web agencies
  • WonderDays Launches the UK's First AI Experience Gift Finder – Gifting Just Got So Much Easier!
  • Nonprofit innovator named Mensa Executive Director
  • Yasmine Roulleau named Managing Director in Vancouver, Canada
  • Agreement to Deliver Thin-Film Solar Technology to Space Solar Array Provider, NASA Collaborative Agreement for Orbital Applications in Power Beaming
  • Iterators LLC Honored with IST82 State Award for Accessibility in Massachusetts
Copyright © 2025 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute